nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—Vandetanib—thyroid cancer	0.347	1	CrCtD
Erlotinib—Gefitinib—Vandetanib—thyroid cancer	0.161	1	CrCrCtD
Erlotinib—kidney cancer—thyroid cancer	0.101	0.509	CtDrD
Erlotinib—lung cancer—thyroid cancer	0.0975	0.491	CtDrD
Erlotinib—MKNK1—Vandetanib—thyroid cancer	0.0203	0.0871	CbGbCtD
Erlotinib—LTK—Vandetanib—thyroid cancer	0.0203	0.0871	CbGbCtD
Erlotinib—SLK—Vandetanib—thyroid cancer	0.017	0.0729	CbGbCtD
Erlotinib—FLT3—Vandetanib—thyroid cancer	0.0147	0.063	CbGbCtD
Erlotinib—EPHA6—Vandetanib—thyroid cancer	0.013	0.0557	CbGbCtD
Erlotinib—MKNK1—Sorafenib—thyroid cancer	0.0122	0.0525	CbGbCtD
Erlotinib—AURKC—Sorafenib—thyroid cancer	0.0122	0.0525	CbGbCtD
Erlotinib—ABL2—Vandetanib—thyroid cancer	0.0117	0.05	CbGbCtD
Erlotinib—EGFR—Vandetanib—thyroid cancer	0.0117	0.05	CbGbCtD
Erlotinib—STK10—Vandetanib—thyroid cancer	0.0117	0.05	CbGbCtD
Erlotinib—MAP2K5—Vandetanib—thyroid cancer	0.0106	0.0455	CbGbCtD
Erlotinib—MAP3K19—Vandetanib—thyroid cancer	0.00976	0.0419	CbGbCtD
Erlotinib—FLT3—Sorafenib—thyroid cancer	0.00885	0.038	CbGbCtD
Erlotinib—ABL1—Vandetanib—thyroid cancer	0.00843	0.0362	CbGbCtD
Erlotinib—EPHA6—Sorafenib—thyroid cancer	0.00782	0.0336	CbGbCtD
Erlotinib—HIPK4—Sorafenib—thyroid cancer	0.00782	0.0336	CbGbCtD
Erlotinib—STK10—Sorafenib—thyroid cancer	0.00703	0.0302	CbGbCtD
Erlotinib—MAP2K5—Sorafenib—thyroid cancer	0.0064	0.0274	CbGbCtD
Erlotinib—MAP3K19—Sorafenib—thyroid cancer	0.00588	0.0252	CbGbCtD
Erlotinib—ORM1—Vandetanib—thyroid cancer	0.00316	0.0135	CbGbCtD
Erlotinib—UGT1A1—Sorafenib—thyroid cancer	0.00211	0.00905	CbGbCtD
Erlotinib—ABCG2—Vandetanib—thyroid cancer	0.00193	0.00826	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—thyroid cancer	0.00148	0.00636	CbGbCtD
Erlotinib—ALB—Vandetanib—thyroid cancer	0.00133	0.0057	CbGbCtD
Erlotinib—ABCG2—Sorafenib—thyroid cancer	0.00116	0.00498	CbGbCtD
Erlotinib—Vandetanib—RET—thyroid cancer	0.000763	1	CrCbGaD
Erlotinib—ABCG2—Doxorubicin—thyroid cancer	0.000704	0.00302	CbGbCtD
Erlotinib—CYP3A5—Sorafenib—thyroid cancer	0.000643	0.00276	CbGbCtD
Erlotinib—CYP2C8—Sorafenib—thyroid cancer	0.000618	0.00265	CbGbCtD
Erlotinib—CYP1A2—Sorafenib—thyroid cancer	0.000479	0.00205	CbGbCtD
Erlotinib—ABCB1—Sorafenib—thyroid cancer	0.000419	0.0018	CbGbCtD
Erlotinib—CYP3A4—Vandetanib—thyroid cancer	0.000416	0.00178	CbGbCtD
Erlotinib—CYP2D6—Sorafenib—thyroid cancer	0.000394	0.00169	CbGbCtD
Erlotinib—PIP4K2C—saliva-secreting gland—thyroid cancer	0.000368	0.031	CbGeAlD
Erlotinib—TNK1—trachea—thyroid cancer	0.000366	0.0308	CbGeAlD
Erlotinib—ULK3—saliva-secreting gland—thyroid cancer	0.000352	0.0296	CbGeAlD
Erlotinib—LTK—head—thyroid cancer	0.00035	0.0295	CbGeAlD
Erlotinib—NR1I2—head—thyroid cancer	0.00035	0.0295	CbGeAlD
Erlotinib—AURKC—thyroid gland—thyroid cancer	0.000341	0.0287	CbGeAlD
Erlotinib—JAK3—thyroid gland—thyroid cancer	0.000316	0.0265	CbGeAlD
Erlotinib—SLK—saliva-secreting gland—thyroid cancer	0.000314	0.0264	CbGeAlD
Erlotinib—AURKC—head—thyroid cancer	0.000302	0.0254	CbGeAlD
Erlotinib—TNK1—thyroid gland—thyroid cancer	0.00029	0.0244	CbGeAlD
Erlotinib—PIP4K2C—trachea—thyroid cancer	0.000284	0.0239	CbGeAlD
Erlotinib—EPHA6—head—thyroid cancer	0.00028	0.0235	CbGeAlD
Erlotinib—JAK3—head—thyroid cancer	0.00028	0.0235	CbGeAlD
Erlotinib—ULK3—trachea—thyroid cancer	0.000271	0.0228	CbGeAlD
Erlotinib—MAP3K19—head—thyroid cancer	0.000254	0.0214	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—thyroid cancer	0.000254	0.00109	CbGbCtD
Erlotinib—CYP3A4—Sorafenib—thyroid cancer	0.000251	0.00108	CbGbCtD
Erlotinib—LTK—lymph node—thyroid cancer	0.000245	0.0206	CbGeAlD
Erlotinib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000243	0.0205	CbGeAlD
Erlotinib—SLK—trachea—thyroid cancer	0.000242	0.0203	CbGeAlD
Erlotinib—CYP2D6—Doxorubicin—thyroid cancer	0.000239	0.00103	CbGbCtD
Erlotinib—ABL2—thyroid gland—thyroid cancer	0.000238	0.02	CbGeAlD
Erlotinib—EGFR—thyroid gland—thyroid cancer	0.000232	0.0195	CbGeAlD
Erlotinib—PIP4K2C—thyroid gland—thyroid cancer	0.000225	0.0189	CbGeAlD
Erlotinib—ULK3—thyroid gland—thyroid cancer	0.000215	0.0181	CbGeAlD
Erlotinib—AURKC—lymph node—thyroid cancer	0.000212	0.0178	CbGeAlD
Erlotinib—MKNK1—thyroid gland—thyroid cancer	0.000202	0.017	CbGeAlD
Erlotinib—PIP4K2C—head—thyroid cancer	0.000199	0.0168	CbGeAlD
Erlotinib—JAK3—lymph node—thyroid cancer	0.000196	0.0165	CbGeAlD
Erlotinib—SLK—thyroid gland—thyroid cancer	0.000191	0.0161	CbGeAlD
Erlotinib—ULK3—head—thyroid cancer	0.00019	0.016	CbGeAlD
Erlotinib—ABL1—saliva-secreting gland—thyroid cancer	0.000188	0.0158	CbGeAlD
Erlotinib—MAP2K5—trachea—thyroid cancer	0.000188	0.0158	CbGeAlD
Erlotinib—TNK1—lymph node—thyroid cancer	0.00018	0.0151	CbGeAlD
Erlotinib—MKNK1—head—thyroid cancer	0.000179	0.0151	CbGeAlD
Erlotinib—STK10—thyroid gland—thyroid cancer	0.000166	0.014	CbGeAlD
Erlotinib—FLT3—lymph node—thyroid cancer	0.000155	0.013	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—thyroid cancer	0.000152	0.000653	CbGbCtD
Erlotinib—MAP2K5—thyroid gland—thyroid cancer	0.000149	0.0125	CbGeAlD
Erlotinib—ABL2—lymph node—thyroid cancer	0.000148	0.0124	CbGeAlD
Erlotinib—STK10—head—thyroid cancer	0.000148	0.0124	CbGeAlD
Erlotinib—ABL1—trachea—thyroid cancer	0.000145	0.0122	CbGeAlD
Erlotinib—EGFR—lymph node—thyroid cancer	0.000144	0.0121	CbGeAlD
Erlotinib—PIP4K2C—lymph node—thyroid cancer	0.00014	0.0117	CbGeAlD
Erlotinib—ULK3—lymph node—thyroid cancer	0.000133	0.0112	CbGeAlD
Erlotinib—MAP2K5—head—thyroid cancer	0.000132	0.0111	CbGeAlD
Erlotinib—MKNK1—lymph node—thyroid cancer	0.000126	0.0106	CbGeAlD
Erlotinib—SLK—lymph node—thyroid cancer	0.000119	0.01	CbGeAlD
Erlotinib—ABCG2—saliva-secreting gland—thyroid cancer	0.000118	0.00997	CbGeAlD
Erlotinib—SLCO2B1—thyroid gland—thyroid cancer	0.000116	0.00973	CbGeAlD
Erlotinib—ABL1—thyroid gland—thyroid cancer	0.000115	0.00964	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	0.000114	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	0.000114	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	0.000114	0.173	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	0.000105	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	0.000105	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	0.000105	0.16	CbGdCrCtD
Erlotinib—STK10—lymph node—thyroid cancer	0.000103	0.0087	CbGeAlD
Erlotinib—SLCO2B1—head—thyroid cancer	0.000103	0.00863	CbGeAlD
Erlotinib—ABL1—head—thyroid cancer	0.000102	0.00856	CbGeAlD
Erlotinib—CYP1B1—thyroid gland—thyroid cancer	9.71e-05	0.00817	CbGeAlD
Erlotinib—MAP2K5—lymph node—thyroid cancer	9.23e-05	0.00777	CbGeAlD
Erlotinib—CYP1A1—trachea—thyroid cancer	8.67e-05	0.0073	CbGeAlD
Erlotinib—CYP1B1—head—thyroid cancer	8.61e-05	0.00725	CbGeAlD
Erlotinib—Haematemesis—Doxorubicin—thyroid cancer	8.15e-05	0.00283	CcSEcCtD
Erlotinib—Ileus—Doxorubicin—thyroid cancer	8e-05	0.00278	CcSEcCtD
Erlotinib—Lung disorder—Doxorubicin—thyroid cancer	8e-05	0.00278	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	7.98e-05	0.00277	CcSEcCtD
Erlotinib—Insomnia—Vandetanib—thyroid cancer	7.92e-05	0.00275	CcSEcCtD
Erlotinib—Erythema multiforme—Sorafenib—thyroid cancer	7.86e-05	0.00273	CcSEcCtD
Erlotinib—Blister—Doxorubicin—thyroid cancer	7.85e-05	0.00273	CcSEcCtD
Erlotinib—Dyspnoea—Vandetanib—thyroid cancer	7.81e-05	0.00271	CcSEcCtD
Erlotinib—Dyspepsia—Vandetanib—thyroid cancer	7.71e-05	0.00267	CcSEcCtD
Erlotinib—Rash pustular—Epirubicin—thyroid cancer	7.67e-05	0.00266	CcSEcCtD
Erlotinib—Decreased appetite—Vandetanib—thyroid cancer	7.61e-05	0.00264	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	7.56e-05	0.00262	CcSEcCtD
Erlotinib—Fatigue—Vandetanib—thyroid cancer	7.55e-05	0.00262	CcSEcCtD
Erlotinib—Rigors—Epirubicin—thyroid cancer	7.49e-05	0.0026	CcSEcCtD
Erlotinib—ORM1—lymph node—thyroid cancer	7.49e-05	0.0063	CbGeAlD
Erlotinib—Mediastinal disorder—Sorafenib—thyroid cancer	7.49e-05	0.0026	CcSEcCtD
Erlotinib—Pain—Vandetanib—thyroid cancer	7.49e-05	0.0026	CcSEcCtD
Erlotinib—Constipation—Vandetanib—thyroid cancer	7.49e-05	0.0026	CcSEcCtD
Erlotinib—Arrhythmia—Sorafenib—thyroid cancer	7.43e-05	0.00258	CcSEcCtD
Erlotinib—Alopecia—Sorafenib—thyroid cancer	7.35e-05	0.00255	CcSEcCtD
Erlotinib—Mental disorder—Sorafenib—thyroid cancer	7.28e-05	0.00253	CcSEcCtD
Erlotinib—Erythema—Sorafenib—thyroid cancer	7.24e-05	0.00251	CcSEcCtD
Erlotinib—Malnutrition—Sorafenib—thyroid cancer	7.24e-05	0.00251	CcSEcCtD
Erlotinib—ABCG2—thyroid gland—thyroid cancer	7.23e-05	0.00608	CbGeAlD
Erlotinib—SLCO2B1—lymph node—thyroid cancer	7.18e-05	0.00604	CbGeAlD
Erlotinib—Gastrointestinal pain—Vandetanib—thyroid cancer	7.16e-05	0.00248	CcSEcCtD
Erlotinib—ABL1—lymph node—thyroid cancer	7.12e-05	0.00599	CbGeAlD
Erlotinib—Rash pustular—Doxorubicin—thyroid cancer	7.1e-05	0.00246	CcSEcCtD
Erlotinib—Cardiovascular disorder—Epirubicin—thyroid cancer	6.96e-05	0.00242	CcSEcCtD
Erlotinib—CYP1A2—thyroid gland—thyroid cancer	6.96e-05	0.00585	CbGeAlD
Erlotinib—Rigors—Doxorubicin—thyroid cancer	6.93e-05	0.00241	CcSEcCtD
Erlotinib—Abdominal pain—Vandetanib—thyroid cancer	6.92e-05	0.0024	CcSEcCtD
Erlotinib—Body temperature increased—Vandetanib—thyroid cancer	6.92e-05	0.0024	CcSEcCtD
Erlotinib—CYP1A1—thyroid gland—thyroid cancer	6.86e-05	0.00577	CbGeAlD
Erlotinib—Cellulitis—Epirubicin—thyroid cancer	6.73e-05	0.00233	CcSEcCtD
Erlotinib—ALB—lymph node—thyroid cancer	6.57e-05	0.00553	CbGeAlD
Erlotinib—Syncope—Sorafenib—thyroid cancer	6.49e-05	0.00225	CcSEcCtD
Erlotinib—Cardiovascular disorder—Doxorubicin—thyroid cancer	6.44e-05	0.00224	CcSEcCtD
Erlotinib—Bone pain—Epirubicin—thyroid cancer	6.39e-05	0.00222	CcSEcCtD
Erlotinib—Loss of consciousness—Sorafenib—thyroid cancer	6.36e-05	0.00221	CcSEcCtD
Erlotinib—Cough—Sorafenib—thyroid cancer	6.32e-05	0.00219	CcSEcCtD
Erlotinib—Inflammation—Epirubicin—thyroid cancer	6.31e-05	0.00219	CcSEcCtD
Erlotinib—Asthenia—Vandetanib—thyroid cancer	6.28e-05	0.00218	CcSEcCtD
Erlotinib—Cellulitis—Doxorubicin—thyroid cancer	6.23e-05	0.00216	CcSEcCtD
Erlotinib—Pruritus—Vandetanib—thyroid cancer	6.2e-05	0.00215	CcSEcCtD
Erlotinib—Musculoskeletal pain—Epirubicin—thyroid cancer	6.19e-05	0.00215	CcSEcCtD
Erlotinib—Arthralgia—Sorafenib—thyroid cancer	6.16e-05	0.00214	CcSEcCtD
Erlotinib—Myalgia—Sorafenib—thyroid cancer	6.16e-05	0.00214	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	6.12e-05	0.00212	CcSEcCtD
Erlotinib—Hepatocellular injury—Epirubicin—thyroid cancer	6.12e-05	0.00212	CcSEcCtD
Erlotinib—CYP1A1—head—thyroid cancer	6.09e-05	0.00512	CbGeAlD
Erlotinib—CYP1B1—lymph node—thyroid cancer	6.03e-05	0.00507	CbGeAlD
Erlotinib—Diarrhoea—Vandetanib—thyroid cancer	5.99e-05	0.00208	CcSEcCtD
Erlotinib—Melaena—Epirubicin—thyroid cancer	5.98e-05	0.00207	CcSEcCtD
Erlotinib—Bone pain—Doxorubicin—thyroid cancer	5.91e-05	0.00205	CcSEcCtD
Erlotinib—Colitis—Epirubicin—thyroid cancer	5.87e-05	0.00204	CcSEcCtD
Erlotinib—Infection—Sorafenib—thyroid cancer	5.87e-05	0.00204	CcSEcCtD
Erlotinib—Skin exfoliation—Epirubicin—thyroid cancer	5.84e-05	0.00203	CcSEcCtD
Erlotinib—Inflammation—Doxorubicin—thyroid cancer	5.84e-05	0.00203	CcSEcCtD
Erlotinib—Shock—Sorafenib—thyroid cancer	5.81e-05	0.00202	CcSEcCtD
Erlotinib—Nervous system disorder—Sorafenib—thyroid cancer	5.79e-05	0.00201	CcSEcCtD
Erlotinib—Dizziness—Vandetanib—thyroid cancer	5.79e-05	0.00201	CcSEcCtD
Erlotinib—Thrombocytopenia—Sorafenib—thyroid cancer	5.78e-05	0.00201	CcSEcCtD
Erlotinib—Neuropathy—Epirubicin—thyroid cancer	5.74e-05	0.00199	CcSEcCtD
Erlotinib—Skin disorder—Sorafenib—thyroid cancer	5.74e-05	0.00199	CcSEcCtD
Erlotinib—Musculoskeletal pain—Doxorubicin—thyroid cancer	5.73e-05	0.00199	CcSEcCtD
Erlotinib—Hepatocellular injury—Doxorubicin—thyroid cancer	5.66e-05	0.00196	CcSEcCtD
Erlotinib—Dry eye—Epirubicin—thyroid cancer	5.65e-05	0.00196	CcSEcCtD
Erlotinib—Anorexia—Sorafenib—thyroid cancer	5.63e-05	0.00195	CcSEcCtD
Erlotinib—Vomiting—Vandetanib—thyroid cancer	5.57e-05	0.00193	CcSEcCtD
Erlotinib—Melaena—Doxorubicin—thyroid cancer	5.53e-05	0.00192	CcSEcCtD
Erlotinib—Rash—Vandetanib—thyroid cancer	5.52e-05	0.00192	CcSEcCtD
Erlotinib—Dermatitis—Vandetanib—thyroid cancer	5.52e-05	0.00191	CcSEcCtD
Erlotinib—Headache—Vandetanib—thyroid cancer	5.49e-05	0.0019	CcSEcCtD
Erlotinib—Colitis—Doxorubicin—thyroid cancer	5.44e-05	0.00189	CcSEcCtD
Erlotinib—Skin exfoliation—Doxorubicin—thyroid cancer	5.41e-05	0.00188	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	5.38e-05	0.00187	CcSEcCtD
Erlotinib—Neuropathy—Doxorubicin—thyroid cancer	5.32e-05	0.00184	CcSEcCtD
Erlotinib—Sepsis—Epirubicin—thyroid cancer	5.31e-05	0.00184	CcSEcCtD
Erlotinib—Dyspnoea—Sorafenib—thyroid cancer	5.27e-05	0.00183	CcSEcCtD
Erlotinib—Dry eye—Doxorubicin—thyroid cancer	5.23e-05	0.00181	CcSEcCtD
Erlotinib—Nausea—Vandetanib—thyroid cancer	5.2e-05	0.0018	CcSEcCtD
Erlotinib—Dyspepsia—Sorafenib—thyroid cancer	5.2e-05	0.0018	CcSEcCtD
Erlotinib—Decreased appetite—Sorafenib—thyroid cancer	5.14e-05	0.00178	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	5.1e-05	0.00177	CcSEcCtD
Erlotinib—Fatigue—Sorafenib—thyroid cancer	5.09e-05	0.00177	CcSEcCtD
Erlotinib—Constipation—Sorafenib—thyroid cancer	5.05e-05	0.00175	CcSEcCtD
Erlotinib—Pain—Sorafenib—thyroid cancer	5.05e-05	0.00175	CcSEcCtD
Erlotinib—Hepatic failure—Epirubicin—thyroid cancer	4.94e-05	0.00171	CcSEcCtD
Erlotinib—Sepsis—Doxorubicin—thyroid cancer	4.91e-05	0.0017	CcSEcCtD
Erlotinib—Gastrointestinal pain—Sorafenib—thyroid cancer	4.83e-05	0.00168	CcSEcCtD
Erlotinib—Renal failure acute—Epirubicin—thyroid cancer	4.81e-05	0.00167	CcSEcCtD
Erlotinib—Abdominal pain—Sorafenib—thyroid cancer	4.67e-05	0.00162	CcSEcCtD
Erlotinib—Body temperature increased—Sorafenib—thyroid cancer	4.67e-05	0.00162	CcSEcCtD
Erlotinib—Renal impairment—Epirubicin—thyroid cancer	4.67e-05	0.00162	CcSEcCtD
Erlotinib—Dermatitis bullous—Epirubicin—thyroid cancer	4.65e-05	0.00161	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—thyroid cancer	4.57e-05	0.00159	CcSEcCtD
Erlotinib—Cerebrovascular accident—Epirubicin—thyroid cancer	4.53e-05	0.00157	CcSEcCtD
Erlotinib—ABCB1—trachea—thyroid cancer	4.51e-05	0.00379	CbGeAlD
Erlotinib—ABCG2—lymph node—thyroid cancer	4.49e-05	0.00378	CbGeAlD
Erlotinib—Renal failure acute—Doxorubicin—thyroid cancer	4.45e-05	0.00154	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	4.44e-05	0.00154	CcSEcCtD
Erlotinib—CYP2D6—head—thyroid cancer	4.4e-05	0.0037	CbGeAlD
Erlotinib—Renal impairment—Doxorubicin—thyroid cancer	4.32e-05	0.0015	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—thyroid cancer	4.3e-05	0.00149	CcSEcCtD
Erlotinib—CYP1A1—lymph node—thyroid cancer	4.26e-05	0.00359	CbGeAlD
Erlotinib—Asthenia—Sorafenib—thyroid cancer	4.24e-05	0.00147	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—thyroid cancer	4.19e-05	0.00146	CcSEcCtD
Erlotinib—Pruritus—Sorafenib—thyroid cancer	4.18e-05	0.00145	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—thyroid cancer	4.13e-05	0.00143	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	4.11e-05	0.00143	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—thyroid cancer	4.07e-05	0.00141	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—thyroid cancer	4.04e-05	0.0014	CcSEcCtD
Erlotinib—Diarrhoea—Sorafenib—thyroid cancer	4.04e-05	0.0014	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	4e-05	0.00139	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—thyroid cancer	3.93e-05	0.00136	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	3.92e-05	0.00136	CcSEcCtD
Erlotinib—Dizziness—Sorafenib—thyroid cancer	3.91e-05	0.00136	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—thyroid cancer	3.84e-05	0.00133	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—thyroid cancer	3.82e-05	0.00133	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—thyroid cancer	3.77e-05	0.00131	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—thyroid cancer	3.76e-05	0.00131	CcSEcCtD
Erlotinib—Vomiting—Sorafenib—thyroid cancer	3.76e-05	0.0013	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—thyroid cancer	3.74e-05	0.0013	CcSEcCtD
Erlotinib—Rash—Sorafenib—thyroid cancer	3.72e-05	0.00129	CcSEcCtD
Erlotinib—Dermatitis—Sorafenib—thyroid cancer	3.72e-05	0.00129	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	3.7e-05	0.00128	CcSEcCtD
Erlotinib—Headache—Sorafenib—thyroid cancer	3.7e-05	0.00128	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—thyroid cancer	3.64e-05	0.00126	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	3.62e-05	0.00126	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—thyroid cancer	3.59e-05	0.00125	CcSEcCtD
Erlotinib—ABCB1—thyroid gland—thyroid cancer	3.56e-05	0.003	CbGeAlD
Erlotinib—Dysphagia—Doxorubicin—thyroid cancer	3.55e-05	0.00123	CcSEcCtD
Erlotinib—Nausea—Sorafenib—thyroid cancer	3.51e-05	0.00122	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—thyroid cancer	3.48e-05	0.00121	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—thyroid cancer	3.47e-05	0.00121	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—thyroid cancer	3.44e-05	0.00119	CcSEcCtD
Erlotinib—Infestation—Epirubicin—thyroid cancer	3.42e-05	0.00119	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—thyroid cancer	3.42e-05	0.00119	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	3.39e-05	0.00118	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—thyroid cancer	3.36e-05	0.00117	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—thyroid cancer	3.36e-05	0.00116	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—thyroid cancer	3.34e-05	0.00116	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—thyroid cancer	3.33e-05	0.00115	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—thyroid cancer	3.32e-05	0.00115	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—thyroid cancer	3.24e-05	0.00112	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—thyroid cancer	3.23e-05	0.00112	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—thyroid cancer	3.21e-05	0.00111	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—thyroid cancer	3.19e-05	0.00111	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—thyroid cancer	3.17e-05	0.0011	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—thyroid cancer	3.17e-05	0.0011	CcSEcCtD
Erlotinib—ABCB1—head—thyroid cancer	3.16e-05	0.00266	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	3.14e-05	0.00109	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—thyroid cancer	3.11e-05	0.00108	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	3.1e-05	0.00108	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—thyroid cancer	3.09e-05	0.00107	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—thyroid cancer	3.09e-05	0.00107	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—thyroid cancer	3.08e-05	0.00107	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—thyroid cancer	3.07e-05	0.00107	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—thyroid cancer	3.07e-05	0.00107	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—thyroid cancer	3.03e-05	0.00105	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—thyroid cancer	3.02e-05	0.00105	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—thyroid cancer	3.01e-05	0.00105	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	3e-05	0.00104	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—thyroid cancer	2.99e-05	0.00104	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—thyroid cancer	2.91e-05	0.00101	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—thyroid cancer	2.87e-05	0.000996	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—thyroid cancer	2.86e-05	0.000991	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—thyroid cancer	2.84e-05	0.000986	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—thyroid cancer	2.84e-05	0.000986	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—thyroid cancer	2.81e-05	0.000974	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—thyroid cancer	2.79e-05	0.000969	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—thyroid cancer	2.79e-05	0.000967	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—thyroid cancer	2.77e-05	0.000961	CcSEcCtD
Erlotinib—Chills—Epirubicin—thyroid cancer	2.76e-05	0.000957	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—thyroid cancer	2.75e-05	0.000952	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—thyroid cancer	2.72e-05	0.000942	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—thyroid cancer	2.69e-05	0.000934	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—thyroid cancer	2.69e-05	0.000933	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—thyroid cancer	2.67e-05	0.000928	CcSEcCtD
Erlotinib—Erythema—Epirubicin—thyroid cancer	2.67e-05	0.000928	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—thyroid cancer	2.66e-05	0.000922	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—thyroid cancer	2.64e-05	0.000914	CcSEcCtD
Erlotinib—Back pain—Epirubicin—thyroid cancer	2.59e-05	0.000898	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—thyroid cancer	2.56e-05	0.000889	CcSEcCtD
Erlotinib—Chills—Doxorubicin—thyroid cancer	2.55e-05	0.000885	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—thyroid cancer	2.54e-05	0.000881	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—thyroid cancer	2.51e-05	0.000872	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—thyroid cancer	2.49e-05	0.000864	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—thyroid cancer	2.48e-05	0.000859	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—thyroid cancer	2.48e-05	0.000859	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—thyroid cancer	2.44e-05	0.000846	CcSEcCtD
Erlotinib—Syncope—Epirubicin—thyroid cancer	2.4e-05	0.000832	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—thyroid cancer	2.39e-05	0.000831	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—thyroid cancer	2.35e-05	0.000816	CcSEcCtD
Erlotinib—Cough—Epirubicin—thyroid cancer	2.33e-05	0.00081	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—thyroid cancer	2.28e-05	0.00079	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—thyroid cancer	2.28e-05	0.00079	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—thyroid cancer	2.28e-05	0.00079	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—thyroid cancer	2.27e-05	0.000787	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.26e-05	0.000785	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—thyroid cancer	2.22e-05	0.00077	CcSEcCtD
Erlotinib—ABCB1—lymph node—thyroid cancer	2.21e-05	0.00186	CbGeAlD
Erlotinib—Oedema—Epirubicin—thyroid cancer	2.18e-05	0.000757	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—thyroid cancer	2.18e-05	0.000755	CcSEcCtD
Erlotinib—Infection—Epirubicin—thyroid cancer	2.17e-05	0.000752	CcSEcCtD
Erlotinib—Cough—Doxorubicin—thyroid cancer	2.16e-05	0.000749	CcSEcCtD
Erlotinib—Shock—Epirubicin—thyroid cancer	2.15e-05	0.000745	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—thyroid cancer	2.14e-05	0.000743	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—thyroid cancer	2.14e-05	0.000742	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—thyroid cancer	2.12e-05	0.000736	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—thyroid cancer	2.11e-05	0.000731	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—thyroid cancer	2.11e-05	0.000731	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—thyroid cancer	2.11e-05	0.000731	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—thyroid cancer	2.1e-05	0.000729	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.09e-05	0.000726	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—thyroid cancer	2.08e-05	0.000722	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—thyroid cancer	2.02e-05	0.000701	CcSEcCtD
Erlotinib—Infection—Doxorubicin—thyroid cancer	2.01e-05	0.000696	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	1.99e-05	0.00069	CcSEcCtD
Erlotinib—Shock—Doxorubicin—thyroid cancer	1.99e-05	0.00069	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—thyroid cancer	1.98e-05	0.000687	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—thyroid cancer	1.98e-05	0.000686	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—thyroid cancer	1.97e-05	0.000685	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—thyroid cancer	1.96e-05	0.000681	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—thyroid cancer	1.95e-05	0.000675	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—thyroid cancer	1.93e-05	0.000668	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—thyroid cancer	1.92e-05	0.000667	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—thyroid cancer	1.9e-05	0.000658	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	1.88e-05	0.000654	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—thyroid cancer	1.88e-05	0.000653	CcSEcCtD
Erlotinib—Constipation—Epirubicin—thyroid cancer	1.87e-05	0.000648	CcSEcCtD
Erlotinib—Pain—Epirubicin—thyroid cancer	1.87e-05	0.000648	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	1.84e-05	0.000639	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—thyroid cancer	1.83e-05	0.000634	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—thyroid cancer	1.8e-05	0.000625	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—thyroid cancer	1.79e-05	0.000619	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—thyroid cancer	1.78e-05	0.000617	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—thyroid cancer	1.76e-05	0.000609	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.74e-05	0.000605	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—thyroid cancer	1.74e-05	0.000604	CcSEcCtD
Erlotinib—Pain—Doxorubicin—thyroid cancer	1.73e-05	0.000599	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—thyroid cancer	1.73e-05	0.000599	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—thyroid cancer	1.73e-05	0.000599	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—thyroid cancer	1.73e-05	0.000599	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.65e-05	0.000573	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—thyroid cancer	1.6e-05	0.000554	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—thyroid cancer	1.6e-05	0.000554	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—thyroid cancer	1.57e-05	0.000543	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—thyroid cancer	1.54e-05	0.000536	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—thyroid cancer	1.49e-05	0.000518	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—thyroid cancer	1.45e-05	0.000503	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—thyroid cancer	1.44e-05	0.000501	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—thyroid cancer	1.43e-05	0.000496	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—thyroid cancer	1.39e-05	0.000482	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—thyroid cancer	1.38e-05	0.00048	CcSEcCtD
Erlotinib—Rash—Epirubicin—thyroid cancer	1.38e-05	0.000478	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—thyroid cancer	1.38e-05	0.000477	CcSEcCtD
Erlotinib—Headache—Epirubicin—thyroid cancer	1.37e-05	0.000474	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—thyroid cancer	1.34e-05	0.000463	CcSEcCtD
Erlotinib—Nausea—Epirubicin—thyroid cancer	1.3e-05	0.00045	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—thyroid cancer	1.28e-05	0.000446	CcSEcCtD
Erlotinib—Rash—Doxorubicin—thyroid cancer	1.27e-05	0.000442	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—thyroid cancer	1.27e-05	0.000441	CcSEcCtD
Erlotinib—Headache—Doxorubicin—thyroid cancer	1.27e-05	0.000439	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—thyroid cancer	1.2e-05	0.000416	CcSEcCtD
Erlotinib—EGFR—Signaling by PDGF—AKT1—thyroid cancer	3.62e-06	0.000197	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDK1—thyroid cancer	3.62e-06	0.000197	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CHST14—thyroid cancer	3.59e-06	0.000196	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	3.59e-06	0.000195	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—KRAS—thyroid cancer	3.56e-06	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—thyroid cancer	3.54e-06	0.000192	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.5e-06	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—AKT1—thyroid cancer	3.5e-06	0.000191	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRG1—thyroid cancer	3.5e-06	0.00019	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.49e-06	0.00019	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNA2—thyroid cancer	3.48e-06	0.000189	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.47e-06	0.000189	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSHR—thyroid cancer	3.45e-06	0.000188	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—AKT1—thyroid cancer	3.43e-06	0.000187	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HPGD—thyroid cancer	3.42e-06	0.000186	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC5A5—thyroid cancer	3.4e-06	0.000185	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRG1—thyroid cancer	3.4e-06	0.000185	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRKAR1A—thyroid cancer	3.4e-06	0.000185	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.38e-06	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KRAS—thyroid cancer	3.36e-06	0.000183	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.36e-06	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDK1—thyroid cancer	3.34e-06	0.000182	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.33e-06	0.000181	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PTEN—thyroid cancer	3.33e-06	0.000181	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.28e-06	0.000179	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—thyroid cancer	3.25e-06	0.000177	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MEN1—thyroid cancer	3.25e-06	0.000177	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.19e-06	0.000174	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC5A5—thyroid cancer	3.17e-06	0.000173	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.16e-06	0.000172	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TERT—thyroid cancer	3.14e-06	0.000171	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KRAS—thyroid cancer	3.13e-06	0.00017	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.05e-06	0.000166	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—BRAF—thyroid cancer	3.05e-06	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—KRAS—thyroid cancer	3.04e-06	0.000166	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—thyroid cancer	3.03e-06	0.000165	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HIF1A—thyroid cancer	3.01e-06	0.000164	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.97e-06	0.000162	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—thyroid cancer	2.97e-06	0.000161	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCND1—thyroid cancer	2.95e-06	0.000161	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—thyroid cancer	2.95e-06	0.000161	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.95e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTCH1—thyroid cancer	2.94e-06	0.00016	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PTEN—thyroid cancer	2.92e-06	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRG1—thyroid cancer	2.9e-06	0.000158	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—thyroid cancer	2.9e-06	0.000158	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HPGD—thyroid cancer	2.9e-06	0.000158	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC5A5—thyroid cancer	2.89e-06	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—thyroid cancer	2.86e-06	0.000156	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—RXRA—thyroid cancer	2.86e-06	0.000156	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PTEN—thyroid cancer	2.85e-06	0.000155	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.8e-06	0.000152	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—KRAS—thyroid cancer	2.8e-06	0.000152	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CHST14—thyroid cancer	2.77e-06	0.000151	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TPR—thyroid cancer	2.76e-06	0.00015	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.72e-06	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SST—thyroid cancer	2.69e-06	0.000146	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRG1—thyroid cancer	2.68e-06	0.000146	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—RXRA—thyroid cancer	2.67e-06	0.000145	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—thyroid cancer	2.66e-06	0.000145	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TPR—thyroid cancer	2.61e-06	0.000142	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—thyroid cancer	2.61e-06	0.000142	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.59e-06	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—thyroid cancer	2.59e-06	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CALCA—thyroid cancer	2.58e-06	0.000141	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.57e-06	0.00014	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KRAS—thyroid cancer	2.55e-06	0.000139	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—thyroid cancer	2.54e-06	0.000138	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—KRAS—thyroid cancer	2.54e-06	0.000138	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—AKT1—thyroid cancer	2.52e-06	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—thyroid cancer	2.52e-06	0.000137	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PTEN—thyroid cancer	2.5e-06	0.000136	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—thyroid cancer	2.49e-06	0.000136	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BRAF—thyroid cancer	2.49e-06	0.000135	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—RXRA—thyroid cancer	2.42e-06	0.000132	CbGpPWpGaD
Erlotinib—EGFR—Disease—TERT—thyroid cancer	2.41e-06	0.000131	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PTEN—thyroid cancer	2.4e-06	0.000131	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TPR—thyroid cancer	2.39e-06	0.00013	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TPR—thyroid cancer	2.38e-06	0.000129	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—thyroid cancer	2.38e-06	0.000129	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.35e-06	0.000128	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.35e-06	0.000128	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—thyroid cancer	2.35e-06	0.000128	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.34e-06	0.000128	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PRKAR1A—thyroid cancer	2.34e-06	0.000127	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDK1—thyroid cancer	2.34e-06	0.000127	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.33e-06	0.000127	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—thyroid cancer	2.31e-06	0.000126	CbGpPWpGaD
Erlotinib—EGFR—Disease—HIF1A—thyroid cancer	2.3e-06	0.000125	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—thyroid cancer	2.24e-06	0.000122	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—thyroid cancer	2.24e-06	0.000122	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGD—thyroid cancer	2.24e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—thyroid cancer	2.23e-06	0.000121	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—thyroid cancer	2.23e-06	0.000121	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—thyroid cancer	2.22e-06	0.000121	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—thyroid cancer	2.19e-06	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—thyroid cancer	2.17e-06	0.000118	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—thyroid cancer	2.17e-06	0.000118	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—thyroid cancer	2.16e-06	0.000118	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTEN—thyroid cancer	2.15e-06	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—thyroid cancer	2.14e-06	0.000116	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.13e-06	0.000116	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.12e-06	0.000115	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—thyroid cancer	2.12e-06	0.000115	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—thyroid cancer	2.1e-06	0.000114	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TPR—thyroid cancer	2.08e-06	0.000113	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.08e-06	0.000113	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC5A5—thyroid cancer	2.07e-06	0.000113	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.05e-06	0.000112	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TPR—thyroid cancer	1.96e-06	0.000107	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.95e-06	0.000106	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—thyroid cancer	1.95e-06	0.000106	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.93e-06	0.000105	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—thyroid cancer	1.92e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—thyroid cancer	1.92e-06	0.000104	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—thyroid cancer	1.92e-06	0.000104	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—thyroid cancer	1.91e-06	0.000104	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—thyroid cancer	1.91e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—thyroid cancer	1.91e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRG1—thyroid cancer	1.88e-06	0.000102	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—thyroid cancer	1.87e-06	0.000102	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—thyroid cancer	1.86e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—thyroid cancer	1.85e-06	0.0001	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—thyroid cancer	1.84e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.83e-06	9.96e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—thyroid cancer	1.82e-06	9.88e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARG—thyroid cancer	1.8e-06	9.82e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.79e-06	9.75e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.79e-06	9.73e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC5A5—thyroid cancer	1.78e-06	9.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.76e-06	9.58e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	1.75e-06	9.54e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—RXRA—thyroid cancer	1.74e-06	9.45e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—thyroid cancer	1.7e-06	9.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—thyroid cancer	1.69e-06	9.18e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—thyroid cancer	1.68e-06	9.17e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—thyroid cancer	1.68e-06	9.16e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.68e-06	9.13e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.67e-06	9.08e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TPR—thyroid cancer	1.66e-06	9.05e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—thyroid cancer	1.65e-06	8.99e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—thyroid cancer	1.64e-06	8.94e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—RXRA—thyroid cancer	1.64e-06	8.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.64e-06	8.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—thyroid cancer	1.63e-06	8.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—thyroid cancer	1.63e-06	8.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HIF1A—thyroid cancer	1.61e-06	8.78e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.6e-06	8.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	1.57e-06	8.52e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.56e-06	8.51e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.56e-06	8.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—thyroid cancer	1.54e-06	8.38e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—thyroid cancer	1.53e-06	8.33e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—thyroid cancer	1.52e-06	8.27e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RXRA—thyroid cancer	1.5e-06	8.19e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RXRA—thyroid cancer	1.5e-06	8.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.48e-06	8.07e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.47e-06	8e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—thyroid cancer	1.47e-06	7.99e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.46e-06	7.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.46e-06	7.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—thyroid cancer	1.45e-06	7.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—thyroid cancer	1.44e-06	7.83e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—thyroid cancer	1.43e-06	7.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	1.42e-06	7.73e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.42e-06	7.72e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—thyroid cancer	1.4e-06	7.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	1.38e-06	7.52e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.35e-06	7.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—thyroid cancer	1.34e-06	7.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—thyroid cancer	1.34e-06	7.27e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—thyroid cancer	1.32e-06	7.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RXRA—thyroid cancer	1.31e-06	7.13e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—thyroid cancer	1.31e-06	7.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—thyroid cancer	1.3e-06	7.06e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TPR—thyroid cancer	1.28e-06	6.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.26e-06	6.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.25e-06	6.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—thyroid cancer	1.24e-06	6.74e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—thyroid cancer	1.24e-06	6.74e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RXRA—thyroid cancer	1.24e-06	6.72e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—thyroid cancer	1.23e-06	6.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	1.22e-06	6.65e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.2e-06	6.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—thyroid cancer	1.2e-06	6.52e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	1.2e-06	6.51e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.17e-06	6.35e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—thyroid cancer	1.15e-06	6.28e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	1.14e-06	6.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—thyroid cancer	1.12e-06	6.08e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—thyroid cancer	1.11e-06	6.05e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—thyroid cancer	1.1e-06	5.97e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—thyroid cancer	1.09e-06	5.94e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—thyroid cancer	1.05e-06	5.72e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RXRA—thyroid cancer	1.05e-06	5.7e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—thyroid cancer	1.04e-06	5.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	1.04e-06	5.66e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—thyroid cancer	1.04e-06	5.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—thyroid cancer	1.03e-06	5.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.02e-06	5.54e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	1.01e-06	5.5e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—thyroid cancer	9.81e-07	5.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—thyroid cancer	9.75e-07	5.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	9.61e-07	5.23e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—thyroid cancer	9.5e-07	5.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—thyroid cancer	9.5e-07	5.17e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—thyroid cancer	9.45e-07	5.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—thyroid cancer	9.41e-07	5.12e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—thyroid cancer	9.21e-07	5.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	9.18e-07	4.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—thyroid cancer	8.77e-07	4.77e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	8.63e-07	4.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—thyroid cancer	8.39e-07	4.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—thyroid cancer	8.38e-07	4.56e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—thyroid cancer	8.28e-07	4.5e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—thyroid cancer	8.15e-07	4.44e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RXRA—thyroid cancer	8.08e-07	4.4e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—thyroid cancer	7.8e-07	4.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—thyroid cancer	7.74e-07	4.21e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—thyroid cancer	7.52e-07	4.1e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—thyroid cancer	7.47e-07	4.07e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—thyroid cancer	7.43e-07	4.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—thyroid cancer	7.22e-07	3.93e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—thyroid cancer	7.13e-07	3.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—thyroid cancer	7.11e-07	3.87e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—thyroid cancer	6.65e-07	3.62e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—thyroid cancer	6.61e-07	3.6e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—thyroid cancer	6.52e-07	3.55e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—thyroid cancer	6.51e-07	3.54e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—thyroid cancer	6.48e-07	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—thyroid cancer	6.42e-07	3.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—thyroid cancer	6.14e-07	3.34e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—thyroid cancer	6.14e-07	3.34e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—thyroid cancer	6.05e-07	3.29e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—thyroid cancer	5.68e-07	3.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—thyroid cancer	5.42e-07	2.95e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—thyroid cancer	5.35e-07	2.91e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.2e-07	2.83e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—thyroid cancer	5.1e-07	2.78e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—thyroid cancer	4.53e-07	2.47e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—thyroid cancer	4.34e-07	2.36e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—thyroid cancer	4.1e-07	2.23e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.01e-07	2.18e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—thyroid cancer	3.76e-07	2.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—thyroid cancer	3.73e-07	2.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—thyroid cancer	3.5e-07	1.9e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—thyroid cancer	3.27e-07	1.78e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—thyroid cancer	3.08e-07	1.68e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—thyroid cancer	2.61e-07	1.42e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—thyroid cancer	2.02e-07	1.1e-05	CbGpPWpGaD
